TAI · 6472.TW
Bora Pharmaceuticals Co., Ltd.
NT$379.00-NT$13.00 (-3.32%)
Bora Pharmaceuticals Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 41.78% below the high.
Loading market information…
TAI · 1795.TW · TWD
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 05:30 AM UTC. Cached market data; not a live quote.
One-year closing-price history · TWD. Historical prices are not a forecast.
Lotus Pharmaceutical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 54.67% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Lotus Pharmaceutical Co., Ltd.’s forward annual dividend is NT$2.57 per share, paid annual. The forward yield is 1.53% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Lotus Pharmaceutical Co., Ltd.’s next earnings report is currently expected on Nov 5, 2026, with estimated earnings per share of NT$4.20. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Lotus Pharmaceutical Co., Ltd.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Lotus Pharmaceutical Co., Ltd. operates as a pharmaceutical enterprise, specializing in the research, development, production, and sale of generic medicines. Its market presence extends across Taiwan, South Korea, the United States, and other global territories. The company primarily targets therapeutic areas such as oncology, cardiology, nephrology, women's health, anti-obesity, and central nervous system conditions with its generic product line. In addition to prescription generics, Lotus also offers a diverse array of over-the-counter drugs. Diversifying its business activities, the firm engages in the wholesale distribution of cosmetics, the retail of specialized clinical equipment, and provides biotechnology consulting. It also handles the sale of pharmaceuticals and medicinal chemicals, conducts marketing campaigns, offers market planning and business intelligence services, and provides advisory on health management and health technology. Furthermore, Lotus delivers a suite of services including project management for pharmaceutical regulatory compliance, data collection, and agency functions. It also operates as a healthcare consultancy and a Contract Research Organization (CRO). Established in 1966, Lotus Pharmaceutical Co., Ltd. maintains its principal office in Taipei City, Taiwan. The company is a subsidiary of Alvogen Emerging Markets Holdings Limited.
Latest available per-share figures in TWD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 09:35 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q1 2025 | May 9, 2025 | NT$5.40+40.26% vs estimate | NT$4.73B+6.16% vs estimate |
|---|
| Q4 2024 | Mar 6, 2025 | NT$4.27+29.39% vs estimate | NT$4.41B+2.34% vs estimate |
|---|
| Q3 2024 | Nov 7, 2024 | NT$5.87-3.93% vs estimate | NT$5.23B-2.83% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
NT$379.00-NT$13.00 (-3.32%)
Bora Pharmaceuticals Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 41.78% below the high.
NT$132.50-NT$5.00 (-3.64%)
Handa Pharmaceuticals, Inc.’s quoted price sits in the upper half of its reported 52-week range, 14.52% below the high.
NT$28.55-NT$0.80 (-2.73%)
Center Laboratories, Inc.’s quoted price sits in the lower half of its reported 52-week range, 41.69% below the high.
NT$79.90-NT$0.50 (-0.62%)
TTY Biopharm Company Limited’s quoted price sits in the upper half of its reported 52-week range, 8.16% below the high.
NT$59.70-NT$0.10 (-0.17%)
YungShin Global Holding Corporation’s quoted price sits in the upper half of its reported 52-week range, 3.71% below the high.
NT$28.80-NT$0.15 (-0.52%)
Synmosa Biopharma Corporation’s quoted price sits in the lower half of its reported 52-week range, 8.54% below the high.
NT$56.70-NT$0.20 (-0.35%)
Standard Chem & Pharm Co. Ltd.’s quoted price sits in the upper half of its reported 52-week range, 6.36% below the high.
NT$23.30-NT$0.20 (-0.85%)
Orient Pharma Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 21.28% below the high.
